News & Media / Newsroom

Latest news

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

February 1, 2024

Bologna, 31 January 2024, 22:01 CET – Alfasigma S.p.A. is pleased to announce the successful completion of the transaction to acquire the Jyseleca® (filgotinib) business from Galapagos NV (Euronext & NASDAQ: GLPG) for up to €170 million. This marks a significant milestone for the company’s international growth strategy and follows both the signing of the agreement announced on 2 January 2024 and of the Letter of Intent announced on 30 October 2023.

Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent

January 2, 2024

Alfasigma S.p.A today announced that it has signed an agreement with Galapagos NV (Euronext & NASDAQ: GLPG) to acquire the Jyseleca® (filgotinib) business for up to €170 million.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

November 8, 2023

Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

November 8, 2023

Bologna, Italy – November 8, 2023 — Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (“Intercept”), at a price of USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes.

Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing in the rheumatology and gastrointestinal areas

October 31, 2023

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced today that it has signed a letter of intent to acquire the Jyseleca® business from Galapagos (Euronext & NASDAQ: GLPG), a global biotechnology company headquartered in Belgium, developing transformational medicines in immunology and oncology.

Alfasigma S.p.A. tender offer for Intercept Pharmaceuticals, Inc. commences

October 11, 2023

Bologna, Italy– October 11, 2023 — Alfasigma S.p.A. (“Alfasigma”) today

Follow us on social media

Press contacts

Corporate Communication & Institutional Relations

Staff

[email protected] +39.051.6489.511

Press Office

[email protected]